UNIGE document Scientific Article
previous document  unige:2427  next document
add to browser collection

Active intravenous drug use during chronic hepatitis C therapy does not reduce sustained virological response rates in adherent patients

Bruggmann, P.
Falcato, L.
Dober, S.
Helbling, B.
Meili, D.
Published in Journal of viral hepatitis. 2008, vol. 15, no. 10, p. 747-752
Abstract SUMMARY: Reluctance has been expressed about treating chronic hepatitis C in active intravenous (IV) drug users (IDUs), and this is found in both international guidelines and routine clinical practice. However, the medical literature provides no evidence for an unequivocal treatment deferral of this risk group. We retrospectively analyzed the direct effect of IV drug use on treatment outcome in 500 chronic hepatitis C patients enrolled in the Swiss Hepatitis C Cohort Study. Patients were eligible for the study if they had their serum hepatitis C virus (HCV) RNA tested 6 months after the end of treatment and at least one visit during the antiviral therapy, documenting the drug use status. Five hundred patients fulfilled the inclusion criteria (199 were IDU and 301 controls). A minimum exposure to 80% of the scheduled cumulative dose of antivirals was reached in 66.0% of IDU and 60.5% of controls (P = NS). The overall sustained virological response (SVR) rate was 63.6%. Active IDU reached a SVR of 69.3%, statistically not significantly different from controls (59.8%). A multivariate analysis for treatment success showed no significant negative influence of active IV drug use. In conclusion, our study shows no relevant direct influence of IV drugs on the efficacy of anti-HCV therapy among adherent patients.
Keywords AdultAntiviral Agents/therapeutic useCohort StudiesDrug Therapy, CombinationFemaleHepacivirus/drug effectsHepatitis C, Chronic/drug therapy/virologyHumansInterferons/classification/genetics/therapeutic useMaleMiddle AgedPatient ComplianceRibavirin/therapeutic useSubstance Abuse, Intravenous/complicationsSwitzerlandTreatment Outcome
PMID: 18637072
Full text
Article (Accepted version) (126 Kb) - document accessible for UNIGE members only Limited access to UNIGE
Research groups Swiss Hepatitis C Cohort Study
Etudes et traitement de l'hépatite C et B (554)
(ISO format)
BRUGGMANN, P. et al. Active intravenous drug use during chronic hepatitis C therapy does not reduce sustained virological response rates in adherent patients. In: Journal of viral hepatitis, 2008, vol. 15, n° 10, p. 747-752. doi: 10.1111/j.1365-2893.2008.01010.x https://archive-ouverte.unige.ch/unige:2427

488 hits

0 download


Deposited on : 2009-08-13

Export document
Format :
Citation style :